Promoting a prescription product is one of the most tightly regulated forms of advertising in the United States. Claims must be consistent with the approved labelling, risk information must be presented with defined prominence, and nearly everything that goes out passes a medical, legal and regulatory review. An agency that has not worked inside that process will produce material that cannot be approved, and the cost shows up as missed launch dates rather than as a rejected concept.
The review process sets the schedule, not the creative
Medical, legal and regulatory review adds weeks to every asset and multiple rounds to anything novel. Build it into the plan with realistic durations and a named reviewer, agree a pre-approved claims and messaging framework so most material passes first time, and expect that a last-minute change requires a full re-review rather than a quick amend.
Fair balance is a design constraint
Presenting benefit requires presenting risk with comparable prominence, and the format rules differ between broadcast, print and digital. That constrains layout, duration and interaction design in ways a general agency will not anticipate. Brief it as a design requirement at the start rather than discovering it when the review comes back.
Unbranded and disease awareness work has its own rules
Educational material that does not name the product is a legitimate and common approach, and it is constrained by rules about when it becomes promotional by implication. The line depends on context, adjacency and linking. Get the position agreed in writing with your regulatory team before building a programme around it.
Adverse event reporting applies to marketing channels
If a person mentions a side effect in a comment, a message or a survey response, an obligation may arise. Any social, community or enquiry channel needs a defined process for identifying and routing those, with trained staff and a timescale. This is the requirement most often missed when a pharmaceutical brand opens a consumer-facing channel.
Questions people ask about pharma marketing company
Do we need a specialist pharma agency?
For anything promoting a prescription product, effectively yes, because the constraint is process fluency rather than creative ability. A general agency can contribute, but somebody on the team must have worked inside the review process before or the schedule will not hold.
Can pharmaceutical brands use social media?
Yes, with a defined moderation and adverse event process, careful handling of user comments, and material that has passed review. The operational burden is real, which is why some brands restrict comments or choose unbranded channels instead.
How is this work priced?
Retainers plus project fees, with more of the budget going to process and review support than most clients expect. Ask what proportion of the estimate is review cycles and asset versioning, since that is the work that actually consumes the hours.
What about promoting to healthcare professionals?
It follows its own rules and channels, and the claims standards are no looser. Professional promotion is generally a separate programme with separate review, and material for one audience should never be repurposed for the other without going through review again.